UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000034297
Receipt number R000039101
Scientific Title Data analyses and biomarkers measurements of J-ADNI
Date of disclosure of the study information 2018/09/27
Last modified on 2018/09/27 18:35:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Data analyses and biomarkers measurements of J-ADNI

Acronym

Data analyses and biomarkers measurements of J-ADNI

Scientific Title

Data analyses and biomarkers measurements of J-ADNI

Scientific Title:Acronym

Data analyses and biomarkers measurements of J-ADNI

Region

Japan


Condition

Condition

Alzheimer's disease
Mild cognitive impairment

Classification by specialty

Neurology Geriatrics Psychiatry
Radiology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purposes are pathophysiological investigation and early diagnosis of Alzheimer's disease using open data of J-ADNI ((Japanese Alzheimer's bDisease Neuroimaging Initiative), which were multi-center cohort study of Alzheimer's disease

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

To find and validate imaging and biomarker predictors for converting from MCI to AD dementia.

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

60 years-old <=

Age-upper limit

84 years-old >=

Gender

Male and Female

Key inclusion criteria

150 cases of normal aged individuals, 300 cases of MCI, 150 cases of early AD, whose language is Japanese.
Living at home, accompanied by a study partner.
The participants should sign agreement forms. In case the participant is not capable of agreeing, the study partner should sign in substitution.
Age: 60-84 years upon enrollment

Criteria for normal aged individuals
MMSE: 24-30
Scores of Wechsler memory Scale-R logical memory II (corrected for education), above the cut-off levels.
education 0-9 years: 3 or above
10-15 years: 5 or above
>16 years 9 or above

Criteria for amnestic MCI
Type 1: complaint of memory disturbance from the participant plus approval by the study partner
Type 2: memory disturbance approved by the study partner, without the subjective complaint of the participant
(excluded in case only with subjective memory complaint, without approval by the study partner)
MMSE: 24-30
Scores of Wechsler memory Scale-R logical memory II (corrected for education), below the cut-off levels.
education 0-9 years: 2 or lower
10-15 years: 4 or lower
>16 years 8 or lower
CDR 0.5 not depressed

Criteria for early AD
MMSE: 20-26
Scores of Wechsler memory Scale-R logical memory II (corrected for education), below the cut-off levels.
education 0-9 years: 2 or lower
10-15 years: 4 or lower
>16 years 8 or lower
CDR 0.5 or 1
Probable AD by the criteria of NINCDS-ADRDA
(Causes or diseases leading to dementia other than AD excluded)

Key exclusion criteria

1. Parkinson' disease, multiple cerebral infarction, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, epilepsy, subdural hematoma, multiple sclerosis, head trauma with sequelae
2. Signs of brain infection, focal brain lesions (eg infarction) that may affect cognitive function.
3. Presence of pacemaker, arterial clip, artificial valves, artificial cochlea, and other magnetic/electroconductive metals in the body that may affect MRI
4. Major depression or bipolar disorder within past 1 year, addiction to alcohol or other drugs within past 2 years, presence of fatal or unstable diseases, vitamin B12 or folate deficiency, syphilis, thyroid function abnormality
5. administration of psychoactive drugs (defined in procedure manual)
6. administration of warfarin

Target sample size

0


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takashi Kato

Organization

National Center for Geriatrics and Gerontology

Division name

Department of Radiology

Zip code


Address

7-430, Morioka, Obu, Aichi, Japan

TEL

0562-46-2311

Email

tkato@ncgg.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takashi Kato

Organization

National Center for Geriatrics and Gerontology

Division name

Department of Radiology

Zip code


Address

7-430, Morioka, Obu, Aichi, Japan

TEL

0562-46-2311

Homepage URL

https://humandbs.biosciencedbc.jp/hum0043-v1

Email

tkato@ncgg.go.jp


Sponsor or person

Institute

National Center for Geriatrics and Gerontology

Institute

Department

Personal name



Funding Source

Organization

The Japan Agency for Medical Research and Development (AMED)

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 09 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2016 Year 08 Month 15 Day

Date of IRB


Anticipated trial start date

2016 Year 08 Month 15 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Clinical/neuropsychological evaluation, neuroimaging work-ups and collection of biofluid samples are undertaken longitudinally at baseline, 6,12,24,36 M (normal individuals), baseline, 6,12,18,24,36M (MCI) and baseline, 6, 12, 24 M (early AD).


Management information

Registered date

2018 Year 09 Month 27 Day

Last modified on

2018 Year 09 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039101


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name